Tag Archives: AXSM

Top 10 Stocks To Watch For 2018

Your Pizza Hut delivery could one day arrive via a self-driving Toyota van.

Toyota unveiled a concept vehicle called e-Palette, which could host a mobile store, act as a ride-sharing service or deliver packages. The announcement was unveiled at International CES in Las Vegas on Monday.

The automaker said it is teaming up with a handful of partners, including Pizza Hut, Amazon, Chinese ridesharing giant Didi and Uber.

“Today, you have to travel to the stores,” Toyota president Akio Toyoda said at the event. “In the future with e-Pallete, the store will come to you.”

Although e-Palette is only a concept vehicle for now, he added that the company plans to pilot the technology at the 2020 Olympic Games in Tokyo. Tests in the U.S. and other areas are envisioned for the early 2020s.

Introducing the first Pizza Hut fully autonomous delivery concept vehicle. Excited for our future with @Toyota #CES2018 pic.twitter.com/YGNQUgijha

Top 10 Stocks To Watch For 2018: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) sawits shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer,but it seems that littlehas gone his way, especially after the company reported earnings early this week. Some analysts took this opportunity to reevaluate their stance on the stock. Although this might be a buy for some, the returns look to be getting smaller.

  • [By Paul Ausick]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6.2% Friday, to post a new 52-week low of $12.90 after closing at $13.75 on Thursday. The stock’s 52-week high is $70.43. Volume was about double the daily average of around 15.9 million shares. The company completed the sale of some skincare brands to L’Or茅al.

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) made waves early on Tuesday after the company offered a plethora of announcements. First the company gave an update on its late-stage psoriasis trial. Along with this success, Valeant reported the sale of a couple of its business segments, bringing in a sizable amount of cash.

  • [By Kumar Abhishek] Valeant Pharmaceuticals(NYSE:VRX) stock jumps after the company sold Dendreon for hefty gains.
    Flickr

    Shares of Valeant (NYSE:VRX) jumped more than 14% in pre-market trading yesterday, after the Canadian drug maker announced its long-awaited asset sale plans. The stock later gave away some of its gains after Moody’s released a report stating that the asset sales will not impact its credit rating or outlook, though Valeant’s bond prices jumped by 4.5%. Valeant is a classic example of a shareholder value destroyer. Once the darling of Wall Street, the stock has lost more than 90% of its value since its peak in 2014 and is down by more 80% in the last one year. The stock has dragged portfolios of the likes of Bill Ackman and Prof. Aswath Damodaran. However, the asset saleprovides a ray of hope for Valeant’s shareholders.

  • [By WWW.THESTREET.COM]

    Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
    Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today!   Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.

  • [By Wayne Duggan]

    Market laggards that could come under additional window dressing selling pressure include Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Endo International plc – Ordinary Shares (NASDAQ: ENDP) and NewLink Genetics Corp (NASDAQ: NLNK).

Top 10 Stocks To Watch For 2018: CVR Refining, LP(CVRR)

Advisors’ Opinion:

  • [By Tyler Crowe]

    For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.

    Refining Margins Q4 2012 Q2 2013
    Valero (NYSE: VLO  ) $12.27 $9.26
    Phillips 66 (NYSE: PSX  ) $13.67 $9.88
    HollyFrontier (NYSE: HFC  ) $24.00 $20.28
    CVR Refining (NYSE: CVRR  ) $28.08 $20.30

    Source: Company Earnings releases

  • [By Robert Rapier]

    CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.

  • [By Lisa Levin]

    Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.

Top 10 Stocks To Watch For 2018: Euro/Yen(EJ)

Advisors’ Opinion:

  • [By Belinda Cao]

    E-House China Holdings Ltd. (EJ), a real estate brokerage, gained 9.2 percent to $9.70, extending it advance to a third week. Its American depositary receipts retreated 3.1 percent Sept. 20 from the highest level since May 2011.

Top 10 Stocks To Watch For 2018: Brink's Company (The)(BCO)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    World Wrestling Entertainment (NYSE: WW) received a pair of downgrades after its earnings report came in below estimates.

    Sell-Side's Most Noteworthy Calls
    Baird downgraded Cardinal Health (NYSE: CAH) to Neutral.
    Imperial downgraded Brinks (NYSE: BCO) to In-Line.
    Jefferies upgraded AK Steel (NYSE: AKS) to Buy.
    Craig-Hallum upgraded LendingClub (NYSE: LC) to Buy.
    Deal Talk

    General Electric (NYSE: GE) was said to be in talks to acquire Baker Hughes (NYSE: BHI), according to sources as reported by Dow Jones. A deal could be valued at as much as $30 billion. However, Bloomberg later reported that a GE spokesperson said they're in talks with Baker Hughes regarding possible partnerships, but not an acquisition. Halliburton (NYSE: HAL) had attempted to acquire Baker Hughes in 2014, but the DoJ sued to block the deal valued at $35 billion.

  • [By Lee Jackson]

    Another hedge fund that is also a director at Brink’s Co. (NYSE: BCO) was busy selling stock this past week. Starboard parted with a total of 650,000 shares of the security and protection company at prices that fell between $51.47 and $52.05. The total for the sale was set at $34 million. Shares closed on Friday at $52.00. The consensus price target is $56, and the52-week range is $26.86 to $53.90.

Top 10 Stocks To Watch For 2018: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Axsome Therapeutics Inc (NASDAQ: AXSM) shares dropped 18 percent to $3.62. Axsome Therapeutics priced 3.74 million shares at $3.74 per share.

    Shares of Canadian Solar Inc. (NASDAQ: CSIQ) were down around 11 percent to $12.10 after the company posted downbeat quarterly earnings and issued a weak forecast.

  • [By William Romov]

    Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

  • [By Jim Robertson]

    On Tuesday, ourUnder the Radar Moversnewsletter suggested shorting small cap clinical-stage biopharmaceutical stock Axsome Therapeutics (NASDAQ: AXSM):

  • [By Paul Ausick]

    Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.

Top 10 Stocks To Watch For 2018: Luby's, Inc.(LUB)

Advisors’ Opinion:

  • [By Monica Gerson]

    Luby’s, Inc. (NYSE: LUB) is expected to post earnings for the latest quarter.

    Simulations Plus, Inc. (NASDAQ: SLP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $5.00 million.

Top 10 Stocks To Watch For 2018: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

Top 10 Stocks To Watch For 2018: Oak Valley Bancorp (CA)(OVLY)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, financial shares fell 0.32 percent. Meanwhile, top losers in the sector included Oak Valley Bancorp (NASDAQ: OVLY), down 7 percent, and AmTrust Financial Services Inc (NASDAQ: AFSI) down 5 percent.

Top 10 Stocks To Watch For 2018: Corbus Pharmaceuticals Holdings, Inc.(CRBP)

Advisors’ Opinion:

  • [By Sean Williams]

    This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.

    GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%

    As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!

  • [By Keith Speights]

    Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.

Top 10 Stocks To Watch For 2018: Texas Roadhouse, Inc.(TXRH)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Texas Roadhouse Inc. (NASDAQ: TXRH) was raised to Buy from Neutral at BTIG Research.

    USG Corp. (NYSE: USG) was reiterated as Hold but the price target was raised to $35 from $29 (versus a $34.23 close) at Jefferies.

  • [By Joe Tenebruso]

    Fortunately, well-chosen dividend-growth stocks can help you accomplish both of these goals. And with its powerful wealth-building combination of increasing dividend payouts and share-price appreciation, Texas Roadhouse (NASDAQ:TXRH)is one of the best available in the market today.

  • [By Teresa Rivas]

    Texas Roadhouse(TXRH) tumbled more than 12% on Wednesday as itsfourth-quarter earningsand revenue fell short of expectations.

    Pixabay

    The restaurant chain said it earned 29 cents a share on revenue of $484.7 million. Analysts were expecting earnings per share of 38 cents on revenue of $497.3 million.

    Same-restaurant sales grew 1.2% at company restaurants and 2% at domestic franchises. For the first 55 days of the first quarter, Texas Roadhouse said that same-store sales rose 1.5%.

    The company also raised its dividend 10.5% to 21 cents a share.

    Some analysts urged investors to keep the faith in the stock.Barclay’s JeffreyBernsteinreiterated an Overweight rating and $47 price target on thestock:

    We believe TXRH fundamentals remain best-in-class. That said, the near-term focus remains on directional comps. And not unlike the broader industry, TXRH comps eased significantly to close 2016. Such led to disappointing 4Q16 results from top to bottom. Importantly, while the brand ‘is not immune’ to industry comp headwinds, the relative outperformance to the category was maintained. Looking to 2017, key guidance metrics were reiterated. While questions remain on whether the recent easing of industry comps will persist, we remain comforted by TXRH’s relative outperformance and easing comps as we move through 2017.

    Maxim’s Stephen Andersonreiterated a Buy rating, although he took his price target down $4, to $52:

    In our view, TXRH is not immune to the broader slowdown in Casual Dining, but we believe the company will emerge stronger than peers in the next few quarters.TXRHs disappointing 4Q16 comp of +1.3% (blended) was pulled down by a rare negative comp month in December (-2.1%), marking the first time this occurred in almost four years. Comps were +3% or better in both October and November, and comps so far in 1Q17 are positive despite a stormy start to the quarter in

  • [By Dan Caplinger]

    Steakhouse chain Texas Roadhouse (NASDAQ:TXRH) has had to deal with an extremely difficult business environment for restaurant companies, and investors know all too well how tough times can hurt major players in the industry. Last quarter, Texas Roadhouse disappointed investors with sluggish results, and the company wanted to start 2017 on a better footing.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, Texas Roadhouse (NASDAQ:TXRH) and Garmin (NASDAQ:GRMN)made large moves following their quarterly earnings announcements.

5 Top Biotech Penny Stocks to Buy with Huge Catalysts in January 2018

Few investments have the profit potential of penny stocks, which are stocks that trade under $5 per share.

Just take a look at Marathon Patent Group Inc. (Nasdaq: MARA), which climbed an astounding 341% during the four trading days of Thanksgiving week.

Biotech penny stocks are especially attractive since successful clinical trial results for their drugs can often send their share prices soaring 300%-plus.

That’s why today we’re giving you five of the top biotech penny stocks to buy that are all reporting clinical trial results in January 2018.

If a stock’s clinical trial results are positive, then the stock can soar. For example, the first stock on this list shot up 213% in July after the U.S. Food and Drug Administration (FDA) accepted the resubmission of its New Drug Application (NDA) for one of its drugs.

Receiving FDA approval for an NDA is typically the last major benchmark a drug must pass before it can be launched.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That’s why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you’re willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…

Now get comfy and grab your calendar, because here’s the first biotech penny stock on our list today…

Biotech Penny Stocks to Buy for January, No. 5: Aeterna Zentaris Inc.

Currently trading at $2 per share, Aeterna Zentaris (Nasdaq: AEZS) makes the drug Macrilen as a potential treatment for growth hormone deficiency in adults.

On July 18, the company announced the FDA accepted its NDA for Macrilen for review. This news sent AEZS shares up from $1.02 to $3.20 in just three trading days, for a gain of 213%.

top biotech penny stocks to buymoneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine-75×113.png 75w, moneymorning.com/wp-content/blogs.dir/1/files/2017/12/spilling-medicine.png 300w” sizes=”(max-width: 200px) 100vw, 200px” title=”top biotech penny stocks to buy” />

Still, before Aeterna can launch the drug Macrilen, its resubmitted NDA must be approved by the FDA. The FDA will announce if it approves Aeterna’s resubmitted NDA on Dec. 30.

Company officials are confident the company will be able to launch Macrilen sometime in the first quarter of 2018.

Keep an eye on AEZS shares leading up to the Dec. 30 announcement, and buy only if you believe the FDA will approve the NDA.

Up next is a stock with a drug that has three chances to pass phase 3 clinical trials…

Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc.

Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.

Unlike other biotech penny stocks, shares of AXSM aren’t “all in” on just one drug’s results.

Axsome has at least three different drugs in clinical trial testing, meaning it has a greater chance of having at least one of its drugs pass. This makes shares of AXSM less risky than a biotech penny stock with only one drug in development.

Specifically, we’re going to focus on Axsome’s AXS-02 drug, which is in two separate phase 3 clinical trials to treat complex regional pain syndrome and knee osteoarthritis associated with bone marrow lesions. The results for these two clinical trials are expected in late December or early January.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

If the AXS-02 drug passes phase 3 clinical trials, the stock could jump significantly.

The company also has a second drug, AXS-05, currently in phase 3 clinical trials for the treatment of treatment-resistant depression. Those results are expected sometime in the first half of 2018, so it’s likely that AXS-02’s results will come out first.

The next company we’ll show you is the cheapest on this list…

Biotech Penny Stocks to Buy for January, No. 3: BioLine Rx Ltd.

Currently trading at $1.09 per share, BioLine Rx Ltd. (Nasdaq: BLRX) develops a broad range of drug candidates to treat cancer, liver fibrosis, and even dry eye syndrome.

BioLine has partnerships with major pharmaceutical companies that help bring some of these drugs to launch once they gain some initial success in clinical trials. These partners include Novartis AG (NYSE: NVS) and Merck & Co. Inc. (NYSE: MRK).

Like Axsome Therapeutics, BioLine is less risky than other biotech penny stocks that only have a single drug in development or single partner. But BioLine’s risk profile is even more diverse, with eight drugs in development and multiple major partnerships to help support it.

The company’s leading drug BL-8040 is being tested in three different phase 2 clinical trials in 2018. The first trial is for the drug’s treatment of pancreatic cancer. Partial data of the trial will be presented between Jan. 18 and 20 at the ASCO 2018 Gastrointestinal Cancers Symposium.

Next up is a company which makes a drug that could provide millions of Americans with the relief they so deserve…

Join the conversation. Click here to jump to comments…

how to invest in the stock market

Bob Rodriguez: Trump Might Be Acting; Huge Financial Crisis Still Looming

15 Worst States for Retirement: 2017

Major Risks Are Looming for US Economy: Merrills Ethan Harris

Raymond James says a group of four advisors has joined its employee channel from Morgan Stanley with about $5 million in yearly fees and commissions and $460 million in client assets.

The four registered reps joining it in Mr. Laurel, New Jersey, now do business as SSG Executive Advisory Group of Raymond James, which includes Todd Sherman, CIMA; Jason Sobin; Michael Francisco; and Brian Baskin, CFP.

The firm says its more than 7,100 indie and employee reps will have access to the innovations by year-end.

You are signed up!

ThinkAdvisor’s TechCenter is an educational resource designed to give you a competitive edge by keeping you abreast of new tech innovations and need-to-know information that can be applied to your business. Resources STRAIGHT-THROUGH PROCESSING FOR THE FINANCIAL SERVICES INDUSTRY

STP can be described as electronically capturing and processing transactions in one pass, from the point of first ‘deal’ to final settlement.

how to invest in the stock market: Monro Muffler Brake, Inc.(MNRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, shares of Monro Muffler Brake (MNRO) plunged 3.1% after Barron’s Leslie Norton panned the stock in this weekend’s issue of the magazine. And wouldn’t you know it? Monro’s shares are skidding lower once again today.

    Mike Mozart/JeepersMedia

    Norton’s argument was straightforward:

    At a recent $62, Rochester, N.Y.based Monro (ticker: MNRO) trades at a lofty 28 times forward earnings, compared with a 10-year average of 21.1, and 17 times earnings for the Standard & Poors 500. With sales growth slowing as competition increases, Monros strategic goal of achieving 15% annual sales gains and 20% profit growth seems distant.

    Any hint of more sluggish sales could push the shares down at least 10%. Bruce Geller, CEO of money manager Dalton Greiner Hartman Maher, who is short the stock, says, A fairly commoditized business with low organic growth deserves a more reasonable multiple of 20 times.

    That would put the stock in the mid-$40s.

    Shares of Monro Muffler Brake have dropped 4% to $57.59 at 3:49 p.m. today, leaving around 20% of downside.

    UPDATE: This post initially misspelled ‘Brake’ as ‘Break.’ It’s been corrected.

how to invest in the stock market: Mayne Pharma Group Limited (MAYNF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ

where to buy penny stocks

North Korea’s rapid development of missile technology comes from an unexpected source…

The Ukraine.

Evidence of this connection was first revealed on Aug. 14 in a report by the International Institute for Strategic Studies (IISS).

The IISS report claimed that Pyongyang’s recent success with intercontinental ballistic missiles (ICBMs) was facilitated by black market purchases of foreign rocket engines and intellectual property.

And evidence to further support the IISS’ claim surfaced just this week…

North Korean Media Let Slip the Country’s Latest Rocket Designs

On Tuesday, North Korean state media released images of dictator Kim Jong Un with what looked like cutting-edge rocket engine designs hung on the walls around him.

Indeed, the isolated regime has made leaps and bounds in its missile and rocket engine technology in recent months, dating back to August 2016 in particular…

Don’t Miss: Trump’s Secret Weapon Set to Foil China’s Master Plan

where to buy penny stocks: Calavo Growers, Inc.(CVGW)

Advisors’ Opinion:

  • [By Shanthi Rexaline]

    Agricultural Produce Companies

    Limoneira Company (NASDAQ: LMNR): -32.1 percent since 2011. Calavo Growers, Inc. (NASDAQ: CVGW): +168.2 percent since 2011.

    Agri-Input Companies — Seeds/ Fertilizers/Pesticides Manufacturers

  • [By Lee Jackson]

    Calavo Growers Inc. (NASDAQ: CVGW) had the man at the top buying stock last week. CEO Lecil Cole purchased 95,000 shares of the avocados and other perishable foods distributor at prices between $55.44 and $56.92 a share. The total for the purchase was set at $5 million. The stock closed the day last Friday at $58.30, in a52-week range of$48.745 to $71.48. The consensus price target is set at $73.17.

where to buy penny stocks: Molex Incorporated(MOLX)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Shares of electronic connector maker Molex Incorporated (MOLX) skyrocketed on Monday morning after reports that the company will be acquired by Koch Industries.

    Koch Industries has agreed to acquire Molex for a total of $7.2 billion. This deal will include all outstanding shares of the company’s Common Stock, Class A Common Stock and Class B Common Stock for $38.50 per share.

    The deal has been approved by the board of directors of both companies. Molex will continue to maintain its current management team and its current headquarters in Lisle, IL.

    Molex shares were up $9.15, or 31.17%, during Monday morning trading. The stock is up 41% YTD.

where to buy penny stocks: Outerwall Inc.(OUTR)

Advisors’ Opinion:

  • [By Monica Gerson]

    Shares of Outerwall Inc (NASDAQ: OUTR) surged over 8 percent in Monday’s after-hours trading session following news for investors the company has begun the process of exploring strategic and financial alternatives. Outerwall’s Board also announced the raising of the company’s quarterly dividend from $0.30 to $0.60 per share. Outerwall shares jumped 8.11 percent to $37.18 in the after-hours trading session.

  • [By Monica Gerson]

    Outerwall (NASDAQ: OUTR) dipped 19.33% to $45.15 in the pre-market session after the company lowered its forecast for the third quarter and full year.

  • [By Lisa Levin]

    Outerwall (NASDAQ: OUTR) plummeted 12.08% to $49.21 after the company lowered its forecast for the third quarter and full year.

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

  • [By Monica Gerson]

    Outerwall (NASDAQ: OUTR) lowered its forecast for the third quarter and full year. Outerwall shares dipped 19.96% to $44.80 in after-hours trading.

where to buy penny stocks: Axsome Therapeutics, Inc.(AXSM)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Tuesday, ourUnder the Radar Moversnewsletter suggested shorting small cap clinical-stage biopharmaceutical stock Axsome Therapeutics (NASDAQ: AXSM):

  • [By Lisa Levin]

    Axsome Therapeutics Inc (NASDAQ: AXSM) shares dropped 18 percent to $3.62. Axsome Therapeutics priced 3.74 million shares at $3.74 per share.

    Shares of Canadian Solar Inc. (NASDAQ: CSIQ) were down around 11 percent to $12.10 after the company posted downbeat quarterly earnings and issued a weak forecast.

where to buy penny stocks: Peregrine Pharmaceuticals Inc.(PPHM)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

where to buy penny stocks: Six Flags Entertainment Corporation New(SIX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

  • [By Lee Jackson]

    Six Flags Entertainment Inc. (NYSE: SIX) also recently had a large buyer acquiring more shares of the company. CEO and the President John Duffey bought a total of 25,000 shares of the theme park giant at $59.93 per share. The total for the trade was posted at $1,498,198. The stock closed last Friday at $59.96. The 52-week range for the shares is $45.24 to $62.69. The consensus price target is $62.43.

  • [By WWW.THESTREET.COM]

    That’s not to say the consumer never leaves the house, but when they do, they shop for their homes at Home Depot (HD) and Home Goods, the TJX Stores (TJX) chain that’s knocking it out of the park. The consumer is also visiting theme parks like Six Flags (SIX) and Walt Disney (DIS) and they’re also going on Carnival Cruises (CCL) .

  • [By WWW.THESTREET.COM]

    All is not lost for retail, however. Cramer continued to recommend the closeout and discount chains like TJX Stores (TJX) , Ollie’s Bargain Outlet (OLLI) and Burlington Stores (BURL) . He was also bullish on those who cater to the millennials, like Six Flags (SIX) , Dave & Busters (PLAY) and Foot Locker (FL) , where trying on shoes never seems to go out of style.